Cargando…

Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation

Detalles Bibliográficos
Autores principales:	Roca, Maria Serena, Moccia, Tania, Iannelli, Federica, Testa, Cristina, Vitagliano, Carlo, Minopoli, Michele, Camerlingo, Rosa, De Riso, Giulia, De Cecio, Rossella, Bruzzese, Francesca, Conte, Mariarosaria, Altucci, Lucia, Di Gennaro, Elena, Avallone, Antonio, Leone, Alessandra, Budillon, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004159/ https://www.ncbi.nlm.nih.gov/pubmed/35410264 http://dx.doi.org/10.1186/s13046-022-02324-2

Ejemplares similares

HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
por: Roca, Maria Serena, et al.
Publicado: (2022)

Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
por: Iannelli, Federica, et al.
Publicado: (2020)

Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance
por: Iannelli, Federica, et al.
Publicado: (2020)

Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation
por: Ciardiello, Chiara, et al.
Publicado: (2019)

Domatinostat Targets the FOXM1–Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2023)

HDAC Class I Inhibitor Domatinostat Preferentially Targets Glioma Stem Cells over Their Differentiated Progeny
por: Nakagawa-Saito, Yurika, et al.
Publicado: (2022)

The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression
por: Srinivas, Nalini, et al.
Publicado: (2023)

Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors
por: Roca, Maria Serena, et al.
Publicado: (2019)

Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression
por: Ciardiello, Chiara, et al.
Publicado: (2016)

Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
por: Bretz, Anne Catherine, et al.
Publicado: (2019)

HDAC2‐dependent miRNA signature in acute myeloid leukemia
por: Conte, Mariarosaria, et al.
Publicado: (2019)

Epigenetic Approaches to Overcome Fluoropyrimidines Resistance in Solid Tumors
por: Grumetti, Laura, et al.
Publicado: (2022)

Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
por: Wobser, Marion, et al.
Publicado: (2019)

HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer
por: Lombardi, Rita, et al.
Publicado: (2021)

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase
por: Di Gennaro, E, et al.
Publicado: (2010)

Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Targeting HDAC2-Mediated Immune Regulation to Overcome Therapeutic Resistance in Mutant Colorectal Cancer
por: Conte, Mariarosaria, et al.
Publicado: (2023)

Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC–MEF2 complexes
por: Nebbioso, Angela, et al.
Publicado: (2009)

Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape
por: Conte, Mariarosaria, et al.
Publicado: (2014)

Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection
por: Costantini, Susan, et al.
Publicado: (2023)

Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype
por: Milone, Maria Rita, et al.
Publicado: (2014)

Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid
por: Hoffman, Mariah M., et al.
Publicado: (2020)

HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction
por: Tian, Shuo, et al.
Publicado: (2018)

HDAC Inhibitors Repress BARD1 Isoform Expression in Acute Myeloid Leukemia Cells via Activation of miR-19a and/or b
por: Lepore, Ilaria, et al.
Publicado: (2013)

Marine-Derived Secondary Metabolites as Promising Epigenetic Bio-Compounds for Anticancer Therapy
por: Conte, Mariarosaria, et al.
Publicado: (2020)

Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets
por: Santaniello, Giovanna, et al.
Publicado: (2022)

FOXM1: Functional Roles of FOXM1 in Non-Malignant Diseases
por: Zhang, Zhenwang, et al.
Publicado: (2023)

Synergistic antitumor interaction between valproic acid and capecitabine in breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2015)

Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity
por: Minopoli, Michele, et al.
Publicado: (2019)

The HDAC inhibitor SAHA regulates CBX2 stability via a SUMO-triggered ubiquitin-mediated pathway in leukemia
por: Di Costanzo, Antonella, et al.
Publicado: (2018)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Molecular Docking Simulations on Histone Deacetylases (HDAC)-1 and -2 to Investigate the Flavone Binding
por: Scafuri, Bernardina, et al.
Publicado: (2020)

HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
por: Passaro, Eugenia, et al.
Publicado: (2021)

Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas
por: Maekawa, Akira, et al.
Publicado: (2016)

Fasting Drives Nrf2-Related Antioxidant Response in Skeletal Muscle
por: Lettieri-Barbato, Daniele, et al.
Publicado: (2020)

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls
por: Esposito Abate, Riziero, et al.
Publicado: (2020)

Honokiol is a FOXM1 antagonist
por: Halasi, Marianna, et al.
Publicado: (2018)

The cell-penetrating FOXM1 N-terminus (M1-138) demonstrates potent inhibitory effects on cancer cells by targeting FOXM1 and FOXM1-interacting factor SMAD3
por: Zhang, Zhenwang, et al.
Publicado: (2019)

Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells
por: Milone, M R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r3ea2gd6m0sm3b9ivgl1kt18ol